Here are the facts about SCLC and NSCLC and how they differ. Small-cell lung cancer is when abnormal cells in your lung grow fast and uncontrollably. It’s an aggressive form of cancer that often ...

Agilent Technologies Inc. today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early ...

Non-small cell lung cancer that has metastasized may cause ... These are not definitive survival rates, and everyone is different. These statistics should be taken as an estimated guide and ...

MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that the United States Adopted Names (USAN ...

There are two basic types of lung cancer: small cell (SCLC), the most aggressive type ... While this data is useful to a degree, survival rates are statistics and don't necessarily give an ...

in third-line non-small cell lung cancer (NSCLC) patients who are resistant to checkpoint inhibitors and chemotherapy. The multicenter, open-label, pivotal Phase 3 trial is designed to provide a ...

Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across ...

An EGFR gene mutation is one of the biomarkers a doctor often tests for after confirming a diagnosis of non-small cell lung cancer (NSCLC ... However, survival statistics are based on people ...

The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncology Servier will ...

today announced the trial design for the expansion of its THIO-101 pivotal Phase 2 trial in non-small cell lung cancer (NSCLC). Following successful outcomes to date in THIO-101, the expansion of ...